Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease

NCT00909558 is registered in ClinicalTrials.gov with Envita Medical Center, Inc. as lead sponsor.

NCT NCT00909558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00909558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Open Label, Single Site, Safety and Efficacy Study of the Effects of Autologous Natural Killer and Natural Killer T Cell Immunotherapy on Malignant Disease
Lead sponsor
Envita Medical Center, Inc.
Phase
Phase 1
Overall status
Suspended
Start date
May 31, 2009
Completion date
Not reported
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colon cancer, glioma, hepatocellular cancer, pancreatic cancer, prostate cancer, squamous cell lung cancer